{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T16:24:39Z","timestamp":1762100679273},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2002,2,1]],"date-time":"2002-02-01T00:00:00Z","timestamp":1012521600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Rheumatol Rep"],"published-print":{"date-parts":[[2002,2]]},"DOI":"10.1007\/s11926-002-0022-0","type":"journal-article","created":{"date-parts":[[2007,6,1]],"date-time":"2007-06-01T21:24:07Z","timestamp":1180733047000},"page":"39-46","source":"Crossref","is-referenced-by-count":6,"title":["Polymyalgia rheumatica\/temporal arteritis: Recent advances"],"prefix":"10.1007","volume":"4","author":[{"given":"Maria-Louise","family":"Barilla-LaBarca","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah J.","family":"Lenschow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr.","given":"Richard D.","family":"Brasington","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"22_CR1","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0889-857X(21)00370-7","volume":"21","author":"WS Wilke","year":"1995","unstructured":"Wilke WS, Hoffman GS: Treatment of corticosteroid resistant giant cell arteritis. Rheum Dis Clin North Am 1995, 21:59\u201371.","journal-title":"Rheum Dis Clin North Am"},{"key":"22_CR2","first-page":"99","volume":"25","author":"S Bahlas","year":"1998","unstructured":"Bahlas S, Ramos-Remus C, Davis P: Clinical outcome of 149 patients with polymyalgia rheumatica and giant cell arteritis. J Rheumatol 1998, 25:99\u2013104.","journal-title":"J Rheumatol"},{"key":"22_CR3","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1002\/art.1780401022","volume":"40","author":"S Gabriel","year":"1997","unstructured":"Gabriel S, Sunku J, Salvarani C, et al.: Adverse outcomes of anti-inflammatory therapy among patients with polymyalgia rheumatica. Arthritis Rheum 1997, 40:1873\u20131878.","journal-title":"Arthritis Rheum"},{"key":"22_CR4","first-page":"1283","volume":"21","author":"G Nesher","year":"1994","unstructured":"Nesher G, Sonnenblick M, Friedlander Y: Analysis of steroid related complications and mortality in temporal arteritis: a 15 year survey of 43 patients. J Rheumatol 1994, 21:1283\u20131286.","journal-title":"J Rheumatol"},{"key":"22_CR5","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1002\/1529-0131(200005)43:5<1041::AID-ANR12>3.0.CO;2-7","volume":"43","author":"CM Weyand","year":"2000","unstructured":"Weyand CM, Fulbright JW, Hunder GG, et al.: Treatment of giant cell arteritis: interleukin-6 as a biologic marker of disease activity. Arthritis Rheum 2000, 43:1041\u20131048.","journal-title":"Arthritis Rheum"},{"key":"22_CR6","first-page":"S32","volume":"18","author":"AC Uddhammar","year":"2000","unstructured":"Uddhammar AC: Von Willebrand factor in polymyalgia rheumatica and giant cell arteritis. Clin Exp Rheumatol 2000, 18:S32\u201333.","journal-title":"Clin Exp Rheumatol"},{"key":"22_CR7","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1007\/s11926-000-0038-2","volume":"2","author":"N Mohan","year":"2000","unstructured":"Mohan N, Kerr G: Spectrum of giant cell vasculitis. Curr Rheumatol Rep 2000, 2:390\u2013395.","journal-title":"Curr Rheumatol Rep"},{"key":"22_CR8","first-page":"S9","volume":"18","author":"MA Cimmino","year":"2000","unstructured":"Cimmino MA, Zaccaria A: Epidemiology of polymyalgia rheumatica. Clin Exp Rheumatol 2000, 18:S9\u201311.","journal-title":"Clin Exp Rheumatol"},{"key":"22_CR9","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0039-6257(97)00052-0","volume":"42","author":"FD Ghanchi","year":"1997","unstructured":"Ghanchi FD, Dutton GN: Current concepts in giant cell (temporal) arteritis. Surv Ophthalmol 1997, 42:99\u2013123.","journal-title":"Surv Ophthalmol"},{"key":"22_CR10","doi-asserted-by":"crossref","first-page":"192","DOI":"10.7326\/0003-4819-123-3-199508010-00006","volume":"123","author":"C Salvarani","year":"1995","unstructured":"Salvarani C, Gabriel SE, O\u2019Fallon WM, Hunder GG: The incidence of giant cell arteritis in Olmsted County, Minnesota: apparent fluctuations in a cyclic pattern. Ann Intern Med 1995, 123:192\u2013194.","journal-title":"Ann Intern Med"},{"key":"22_CR11","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1093\/rheumatology\/39.12.1396","volume":"39","author":"E Reinhold-Keller","year":"2000","unstructured":"Reinhold-Keller E, Zeidler A, Gutfleisch J, et al.: Giant cell arteritis is more prevalent in urban than in rural populations: results of an epidemiological study of primary systemic vasculitides in Germany. Rheumatology 2000, 39:1396\u20131402.","journal-title":"Rheumatology"},{"key":"22_CR12","first-page":"517","volume":"27","author":"CM Weyand","year":"2000","unstructured":"Weyand CM: The pathogenesis of giant cell arteritis. J Rheumatol 2000, 27:517\u2013522.","journal-title":"J Rheumatol"},{"key":"22_CR13","doi-asserted-by":"publisher","first-page":"S37","DOI":"10.1016\/S0167-5273(00)00187-X","volume":"75","author":"Canto AJ Dal","year":"2000","unstructured":"Dal Canto AJ, Virgin HW: Animal models of infection-mediated vasculitis: implications for human disease. Int J Cardiol 2000, 75:S37-S45.","journal-title":"Int J Cardiol"},{"key":"22_CR14","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1177\/030098589503200205","volume":"32","author":"CA Dangler","year":"1995","unstructured":"Dangler CA, Baker SE, Njenga MK, et al.: Murine cytomegalovirusassociated arteritis. Vet Pathol 1995, 32:127\u2013133.","journal-title":"Vet Pathol"},{"key":"22_CR15","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1084\/jem.188.3.577","volume":"188","author":"RM Presti","year":"1998","unstructured":"Presti RM, Pollock JL, Dal Canto AJ, et al.: Interferon-gamma regulates acute and latent murine cytomegalovirus infection and chronic disease of the great vessels. J Exp Med 1998, 188:577\u2013588.","journal-title":"J Exp Med"},{"key":"22_CR16","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1038\/nm1297-1346","volume":"3","author":"KE Weck","year":"1997","unstructured":"Weck KE, Dal Canto AJ, Gould JD, et al.: Murine gamma-herpesvirus 68 causes large vessel arteritis in mice lacking interferon-gamma responsiveness: a new model for virus induced vascular disease. Nat Med 1997, 3:1346\u20131353.","journal-title":"Nat Med"},{"key":"22_CR17","first-page":"S12","volume":"18","author":"H Elling","year":"2000","unstructured":"Elling H, Olsson AT, Elling P: Human Parvovirus and giant cell arteritis: a selective arteritic impact? Clin Exp Rheumatol 2000, 18:S12-S14.","journal-title":"Clin Exp Rheumatol"},{"key":"22_CR18","first-page":"2718","volume":"27","author":"G Rimenti","year":"2000","unstructured":"Rimenti G, Blasi F, Cosentini R, et al.: Temporal arteritis associated with Chlamydia pneumoniae DNA detected in an artery specimen. J Rheumatol 2000, 27:2718\u20132720.","journal-title":"J Rheumatol"},{"key":"22_CR19","first-page":"299","volume":"15","author":"A Uddhammar","year":"1997","unstructured":"Uddhammar A, Boman J, Juto P, et al.: Antibodies against Chlamydia pneumoniae, cytomegalovirus, enteroviruses and respiratory syncytial virus in patients with polymyalgia rheumatica. Clin Exp Rheumatol 1997, 15:299\u2013302.","journal-title":"Clin Exp Rheumatol"},{"key":"22_CR20","first-page":"361","volume":"26","author":"P Duhaut","year":"1999","unstructured":"Duhaut P, Bosshar S, Calvet A, et al.: Giant cell arteritis, polymyalgia rheumatica, and viral hypotheses: a multicenter, prospective case-control study. J Rheumatol 1999, 26:361\u2013369.","journal-title":"J Rheumatol"},{"key":"22_CR21","first-page":"S6","volume":"18","author":"GG Hunder","year":"2000","unstructured":"Hunder GG: Clinical features of GCA\/PMR. Clin Exp Rheumatol 2000, 18:S6-S8.","journal-title":"Clin Exp Rheumatol"},{"key":"22_CR22","first-page":"122","volume":"33","author":"GG Hunder","year":"1990","unstructured":"Hunder GG, Bloch DA, Michel BA, et al.: The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum 1990, 33:122\u2013128.","journal-title":"Arthritis Rheum"},{"key":"22_CR23","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1053\/sarh.2000.8366","volume":"30","author":"F Cantini","year":"2000","unstructured":"Cantini F, Salvarani C, Olivieri I, et al.: Erythrocyte sedimentation rate and C-reactive protein in the evaluation of disease activity and severity in polymyalgia rheumatica: a prospective follow-up study. Semin Arthritis Rheum 2000, 30:17\u201324. Discusses the frequency and clinical features of PMR patients with normal ESRs and compares the ESR and CRP during disease relapses.","journal-title":"Semin Arthritis Rheum"},{"key":"22_CR24","first-page":"S34","volume":"18","author":"VM Martinez-Taboada","year":"2000","unstructured":"Martinez-Taboada VM, Blanco R, Rodriguez-Valverde V: Polymyalgia rheumatica with normal erythrocyte sedimentation rate: clinical aspects. Clin Exp Rheumatol 2000, 18:S34\u201337.","journal-title":"Clin Exp Rheumatol"},{"key":"22_CR25","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1053\/sarh.2001.16650","volume":"30","author":"MA Gonzalez-Gay","year":"2001","unstructured":"Gonzalez-Gay MA, Garcia-Porrua C, Llorca J, et al.: Biopsy-negative giant cell arteritis: clinical spectrum and predictive factors for positive temporal artery biopsy. Semin Arthritis Rheum 2001, 30:249\u2013256. Discusses the frequency and clinical features of biopsy-negative giant cell arteritis.","journal-title":"Semin Arthritis Rheum"},{"key":"22_CR26","first-page":"S38","volume":"18","author":"P Pavlica","year":"2000","unstructured":"Pavlica P, Barozzi L, Salvarani C, et al.: Magnetic resonance imaging in the diagnosis of PMR. Clin Exp Rheumatol 2000, 18:S38\u201339.","journal-title":"Clin Exp Rheumatol"},{"key":"22_CR27","doi-asserted-by":"crossref","first-page":"27","DOI":"10.7326\/0003-4819-127-1-199707010-00005","volume":"127","author":"C Salvarani","year":"1997","unstructured":"Salvarani C, Cantini F, Olivieri I, et al.: Proximal bursitis in active polymyalgia rheumatica. Ann Intern Med 1997, 127:27\u201331.","journal-title":"Ann Intern Med"},{"key":"22_CR28","first-page":"S40","volume":"18","author":"WA Schmidt","year":"2000","unstructured":"Schmidt WA: Doppler ultrasonography in the diagnosis of giant cell arteritis. Clin Exp Rheumatol 2000, 18:S40\u201342.","journal-title":"Clin Exp Rheumatol"},{"key":"22_CR29","first-page":"1570","volume":"24","author":"WA Schmidt","year":"1997","unstructured":"Schmidt WA, Kraft HE, Vorpahl K, et al.: Color duplex ultrasonography in the diagnosis of temporal arteritis. New Engl J Med 1997, 24:1570\u20131574.","journal-title":"New Engl J Med"},{"key":"22_CR30","first-page":"S366","volume":"43","author":"C Salvarini","year":"2000","unstructured":"Salvarini C, Silingardi M, Ghirarduzzi A, et al.: Is duplux ultrasonography useful for the diagnosis of temporal arteritis? Arthritis Rheum 2000, 43:S366.","journal-title":"Arthritis Rheum"},{"key":"22_CR31","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/S0002-9343(99)00424-6","volume":"108","author":"D Blockmans","year":"2000","unstructured":"Blockmans D, Stroobants S, Maes A, Mortelmans L: Positron emission tomography in giant cell arteritis and polymyalgia rheumatica: evidence for inflammation of the aortic arch. Am J Med 2000, 108:246\u2013269. Discusses the high specificity of PET scanning with radiolabeled fluoro-18-deoxyglucose in the diagnosis of PMR\/GCA. Supports the arguments that PMR is a form of vasculitis, and that the large arteries and temporal arteries may be affected in these diseases.","journal-title":"Am J Med"},{"key":"22_CR32","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1080\/03009749950155445","volume":"28","author":"JT Gran","year":"1999","unstructured":"Gran JT: Current therapy of polymyalgia rheumatica. Scand J Rheumatol 1999, 28:269\u2013272.","journal-title":"Scand J Rheumatol"},{"key":"22_CR33","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1093\/rheumatology\/31.2.103","volume":"31","author":"AB Myles","year":"1992","unstructured":"Myles AB, Perera T, Ridley MG: Prevention of blindness in giant cell arteritis by corticosteroid treatment. Br J Rheumatol 1992, 31:103\u2013105.","journal-title":"Br J Rheumatol"},{"key":"22_CR34","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/S0025-7125(05)70511-3","volume":"81","author":"GG Hunder","year":"1997","unstructured":"Hunder GG: Giant cell arteritis and polymyalgia rheumatica. Med Clin North Am 1997, 81:195\u2013219.","journal-title":"Med Clin North Am"},{"key":"22_CR35","doi-asserted-by":"crossref","first-page":"613","DOI":"10.7326\/0003-4819-82-5-613","volume":"82","author":"GG Hunder","year":"1975","unstructured":"Hunder GG, Sheps SG, Allen GL, Joyce JW: Daily and alternateday corticosteroid regimens in treatment of giant cell arteritis: comparison in a prospective study. Ann Intern Med 1975, 82:613\u2013618.","journal-title":"Ann Intern Med"},{"key":"22_CR36","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1093\/rheumatology\/37.2.189","volume":"37","author":"B Dasgupta","year":"1998","unstructured":"Dasgupta B, Dolan AL, Panayi GS, Fernandes L: An initially double blind controlled 96 week trial of depot methylprednisolone against oral prednisolone in the treatment of polymyalgia rheumatica. Br J Rheumatol 1998, 37:189\u2013195.","journal-title":"Br J Rheumatol"},{"key":"22_CR37","first-page":"1470","volume":"27","author":"C Salvarani","year":"2000","unstructured":"Salvarani C, Cantini F, Olivieri I, et al.: Corticosteroid injections in polymyalgia rheumatica: a double blind, prospective, randomized, placebo controlled study. J Rheumatol 2000, 27:1470\u20131476.","journal-title":"J Rheumatol"},{"key":"22_CR38","first-page":"S56","volume":"18","author":"C Li","year":"2000","unstructured":"Li C, Dasgupta B: Corticosteroids in polymyalgia rheumatica \u2014a review of different treatment schedules. Clin Exp Rheumatol 2000, 18:S56\u201357.","journal-title":"Clin Exp Rheumatol"},{"key":"22_CR39","first-page":"S163","volume":"43","author":"P Cacoub","year":"2000","unstructured":"Cacoub P, Chemlal K, Khalifa P, et al.: Deflazacort versus prednisone in patients with giant cell arteritis: a randomized, double blind comparative trial studying the effects on bone mass loss. Arthritis Rheum 2000, 43:S163.","journal-title":"Arthritis Rheum"},{"key":"22_CR40","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1136\/ard.55.2.143","volume":"55","author":"MR Krogsgaard","year":"1996","unstructured":"Krogsgaard MR, Thamsborg G, Lund B: Changes in bone mass during low dose corticosteroid treatment in patients with polymyalgia rheumatica: a double blind, prospective comparison between prednisolone and deflazacort. Ann Rheum Dis 1996, 55:143\u2013146.","journal-title":"Ann Rheum Dis"},{"key":"22_CR41","first-page":"624","volume":"23","author":"GF Ferraccioli","year":"1996","unstructured":"Ferraccioli GF, Salaffi F, De Vita S, et al.: Methotrexate in polymyalgia rheumatica: preliminary results of an open, randomized study. J Rheumatol 1996, 23:624\u2013628.","journal-title":"J Rheumatol"},{"key":"22_CR42","first-page":"1550","volume":"23","author":"HL Feinberg","year":"1996","unstructured":"Feinberg HL, Sherman JD, Schrepferman CG, et al.: The use of methotrexate in polymyalgia rheumatica. J Rheumatol 1996, 23:1550\u20131552.","journal-title":"J Rheumatol"},{"key":"22_CR43","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1136\/ard.55.4.218","volume":"55","author":"MJ Veen Van der","year":"1996","unstructured":"Van der Veen MJ, Dinant HJ, van Booma-Frankfort C, et al.: Can methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis? Ann Rheum Dis 1996, 55:218\u2013223.","journal-title":"Ann Rheum Dis"},{"key":"22_CR44","doi-asserted-by":"publisher","first-page":"S115","DOI":"10.1002\/1529-0131(200006)43:6<1191::AID-ANR1>3.0.CO;2-R","volume":"43","author":"G Hoffman","year":"2000","unstructured":"Hoffman G, Cid M, Hellmann D, et al.: A multicenter placebo controlled study of methotrexate in giant cell arthritis. Arthritis Rheum 2000, 43:S115. Large multicenter, randomized, prospective, placebo-controlled trial comparing prednisone alone with prednisone plus methotrexate in the treatment of newly diagnosed GCA.","journal-title":"Arthritis Rheum"},{"key":"22_CR45","doi-asserted-by":"crossref","first-page":"106","DOI":"10.7326\/0003-4819-134-2-200101160-00010","volume":"134","author":"JA Jover","year":"2001","unstructured":"Jover JA, Hernandez-Garcia C, Morado IC, et al.: Combined treatment of giant-cell arteritis with methotrexate and prednisone. Ann Intern Med 2001, 134:106\u2013114. Randomized, double-blind, placebo-controlled trial comparing prednisone and prednisone plus methotrexate in newly diagnosed GCA.","journal-title":"Ann Intern Med"},{"key":"22_CR46","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1136\/ard.45.2.136","volume":"45","author":"Silva M De","year":"1986","unstructured":"De Silva M, Hazleman BL: Azathioprine in giant cell arteritis\/ polymyalgia rheumatica: a double blind study. Ann Rheum Dis 1986, 45:136\u2013138.","journal-title":"Ann Rheum Dis"},{"key":"22_CR47","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1002\/art.1780260521","volume":"30","author":"P Doury","year":"1983","unstructured":"Doury P, Pattin S, Eulry F, Thabaut A: The use of dapsone in the treatment of giant cell arteritis and polymyalgia rheumatica [letter]. Arthritis Rheum 1983, 30:689\u2013690.","journal-title":"Arthritis Rheum"},{"key":"22_CR48","first-page":"879","volume":"15","author":"P Boesen","year":"1988","unstructured":"Boesen P, Dideriksen K, Stentoft J, Jensen MK: Dapsone in temporal arteritis and polymyalgia rheumatica [letter]. J Rheumatol 1988, 15:879\u2013880.","journal-title":"J Rheumatol"},{"key":"22_CR49","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/0002-9343(88)90616-X","volume":"85","author":"E Reinitz","year":"1988","unstructured":"Reinitz E, Aversa A: Long-term treatment of temporal arteritis with dapsone [letter]. Am J Med 1988, 85:456\u2013457.","journal-title":"Am J Med"},{"key":"22_CR50","first-page":"694","volume":"11","author":"F Liozon","year":"1993","unstructured":"Liozon F, Vidal E, Barrier J: Dose dapsone have a role in the treatment of temporal arteritis with regard to efficacy and toxicity? Clin Exp Rheumatol 1993, 11:694\u2013695.","journal-title":"Clin Exp Rheumatol"},{"key":"22_CR51","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1093\/rheumatology\/37.4.464","volume":"37","author":"C Schaufelberger","year":"1998","unstructured":"Schaufelberger C, Andersson R, Nordborg E: No additive effect of cyclosporin A compared with glucocorticoid treatment alone in giant cell arteritis: results of an open, controlled, randomized study. Br J Rheumatol 1998, 37:464\u2013465.","journal-title":"Br J Rheumatol"},{"key":"22_CR52","first-page":"485","volume":"61","author":"Guennec P Le","year":"1994","unstructured":"Le Guennec P, Dromer C, Sixou L, et al.: Treatment of Horton disease. Value of synthetic antimalarials. Apropos of a retrospective study of 36 patients. Revue du rheumatisme. Edition Francaise 1994, 61:485\u2013490.","journal-title":"Edition Francaise"},{"key":"22_CR53","first-page":"373","volume":"232","author":"Vita S De","year":"1992","unstructured":"De Vita S, Tavoni A, Jeracitano G, et al.: Treatment of giant cell arteritis with cyclophosphamide pulses [letter]. J Intern Med 1992, 232:373\u2013375.","journal-title":"J Intern Med"},{"key":"22_CR54","first-page":"1451","volume":"24","author":"N Galezowski","year":"1997","unstructured":"Galezowski N, Nguyen TB, Blanche P: Sulfamethoxazole\/ trimethoprim therapy for polymyalgia rheumatica. Report of 5 cases [letter]. J Rheumatol 1997, 24:1451\u20131452.","journal-title":"J Rheumatol"},{"key":"22_CR55","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1093\/rheumatology\/37.3.292","volume":"37","author":"G Pearce","year":"1998","unstructured":"Pearce G, Ryan PFJ, Delmas PD, et al.: The deleterious effects of low-dose corticosteroids on bone density in patients with polymyalgia rheumatica. Br J Rheumatol 1998, 37:292\u2013299.","journal-title":"Br J Rheumatol"}],"container-title":["Current Rheumatology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-002-0022-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11926-002-0022-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-002-0022-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-002-0022-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,14]],"date-time":"2021-08-14T13:33:16Z","timestamp":1628947996000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11926-002-0022-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,2]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2002,2]]}},"alternative-id":["22"],"URL":"https:\/\/doi.org\/10.1007\/s11926-002-0022-0","relation":{},"ISSN":["1523-3774","1534-6307"],"issn-type":[{"value":"1523-3774","type":"print"},{"value":"1534-6307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,2]]}}}